<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439371</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1201</org_study_id>
    <secondary_id>2017-A03572-51</secondary_id>
    <nct_id>NCT03439371</nct_id>
  </id_info>
  <brief_title>Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia</brief_title>
  <acronym>MTSA</acronym>
  <official_title>A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and the Tolerance of Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and the tolerance of the micro-transplantation in
      elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with a median age at
      diagnosis of 65 years. Outcomes of AML in elderly population remain unsatisfactory with low
      rates of complete remission, poor disease-free and overall survival. Therapeutic management
      of older patients with AML deals with patient-related features (i.e. comorbid conditions and
      performance status) as well as disease-related prognostic factors (i.e. cytogenetics and
      molecular genetics). Even if allogeneic hematopoietic-cell transplantation provides the
      strongest antineoplasic effect, this treatment option remains limited for older patients
      owing to toxicities, the development of significant graft-versus-host disease (GVHD) and
      logistics of donor availability. More recently, micro-transplantation has emerged as an
      alternative strategy based on the infusion of mobilized HLA-mismatched related donor cells
      after induction chemotherapy, thus exerting a graft-versus-leukemia effect without
      substantial donor engraftment and GVHD. Therefore, there is much of interest in investigating
      the efficacy and the safety of this method for older patients with AML who are not candidates
      for allogeneic stem cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of overall survival will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic recovery</measure>
    <time_frame>3 months</time_frame>
    <description>Number of platelets will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic recovery</measure>
    <time_frame>3 months</time_frame>
    <description>Number of neutrophils will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic recovery</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of leukaemic blasts will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of complete remission :</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD (graft versus host disease)</measure>
    <time_frame>2 years</time_frame>
    <description>Presence of graft versus host disease will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Median overall survival will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Median progression-free survival will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microchimerism</measure>
    <time_frame>3 months</time_frame>
    <description>Presence of microchimerism will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>HLA-mismatched micro-transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-mismatched micro-transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HLA-mismatched micro-transplantation after induction chemotherapy</intervention_name>
    <description>HLA-mismatched micro-transplantation after induction chemotherapy</description>
    <arm_group_label>HLA-mismatched micro-transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affiliated to a social security regimen or beneficiary of the same

          -  Signed written informed consent form

          -  Patient, ≥ 60 years-old - &lt; 75 years-old, with established diagnosis of de novo or
             secondary AML with intermediate-risk or adverse-risk cytogenetic profile, or with
             established myelodysplasic syndromes (RAEB), in pathologically confirmed complete
             remission following anti-leukemic induction therapy (&lt;5% blasts)

          -  Contra-indication to conditioning regimen in conventional allogeneic transplantation

        Exclusion Criteria:

          -  Patient with established diagnosis of acute myeloid leukemia with standard-risk
             cytogenetic profile

          -  Promyelocytic leukemia t(15;17)

          -  CBF-AML t(8;21) or inv(16)

          -  Normal karyotype with a favorable molecular profile: NPM1+ and FLT3-; NPM1+, FLT3- and
             double mutation CEBPα or chronic myeloid leukemia in blastic phase

          -  Patient under guardianship or deprived of his liberty or any condition that may affect
             the patient's ability to understand and sign the informed consent

          -  Refusing participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Cornillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Cornillon, MD</last_name>
    <phone>04 77 91 67 26</phone>
    <phone_ext>+33</phone_ext>
    <email>jerome.cornillon@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Daguenet, PhD</last_name>
    <phone>04 77 91 70 89</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.daguenet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques-Olivier Bay, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques-Olivier Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme Cornillon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme Cornillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Tavernier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Guyotat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Lejeune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Micro-transplantation</keyword>
  <keyword>Elderly</keyword>
  <keyword>Graft-versus-leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

